Core Viewpoint - Jiangsu Haipu Functional Materials Co., Ltd. successfully completed a B+ round financing of nearly 100 million yuan, led by Huatai Zijin and followed by Dunxing Capital [1] Group 1: Financing and Investment - The financing amount is close to 100 million yuan [1] - The round was led by Huatai Zijin with participation from Dunxing Capital [1] Group 2: Strategic Directions - The company will focus on two strategic directions: enhancing R&D efforts and improving operational efficiency [1] - R&D efforts will concentrate on high-performance adsorbents, high-resolution chromatography fillers, and special separation membranes [1] - Operational improvements will support global market expansion, high-end production line construction, and capacity enhancement [1] Group 3: Company Overview - Haipu was established in August 2013, with a registered capital of 45.8334 million yuan [1] - The company specializes in the R&D and industrialization of purification and carrier new materials [1] - Haipu aims to provide high-performance and sustainable separation and purification solutions for industries such as new energy, biomedicine, and nuclear industry [1] Group 4: Business Matrix - The company has developed a business matrix driven by energy resources and life sciences across six strategic areas [1] - Haipu has established a complete layout covering core technology R&D, large-scale product manufacturing, and full-scene application implementation [1] Group 5: Ownership Structure - The actual controller of Haipu is Cai Jianguo, who holds a total shareholding ratio of 41.45% and a voting power of 42.21% [1] - Cai Jianguo serves as the chairman of the company [1]

Core Insights - Jiangsu Haipu Functional Materials Co., Ltd. has recently completed a nearly 100 million yuan B+ round financing led by Huatai Zijin and followed by Dunxing Capital [2] - The company specializes in high-performance adsorption and separation materials, focusing on the independent research and industrial application of "purification and carrier" new materials [2] - Haipu has established a complete technology matrix in six strategic areas, including lithium extraction from salt lakes and pharmaceutical purification, driven by energy resources and life sciences [2] Financing Purpose - The financing will primarily be used for two core directions: increasing R&D investment in high-performance adsorbents, high-resolution chromatography fillers, and special separation membranes, and strengthening operational capabilities for global market expansion and production capacity enhancement [3] - The goal is to accelerate the efficient transformation of "technology-product-market" and enhance the company's supply capacity of key materials in the global energy and biopharmaceutical industries [3] Investment Rationale - The investment in Haipu is based on a deep recognition of its technological strength and strategic prospects, aligning with national strategies for new materials and biomanufacturing [3] - The company possesses a complete independent intellectual property system and has established a unique technological moat in high-growth areas of energy resources and life sciences [3] Investment Perspective - The successful financing of Haipu reflects a strong vote of confidence from venture capital institutions in the hard technology sector and serves as a typical case of collaborative empowerment within the venture capital ecosystem [4] - Recent supportive policies from multiple government departments encourage investment in early-stage, small-scale, and hard technology projects, with Haipu's key new materials field being a focus area [5] - The management structure of Huatai Zijin and Dunxing Capital demonstrates a commitment to responsible fund management and project empowerment, which is essential for the healthy development of the industry [5]

Group 1 - The company announced plans to initiate the process for issuing H-shares and listing on the Hong Kong Stock Exchange to enhance its international presence and brand recognition [1] - The board of directors has authorized the management to start preparatory work for the H-share listing, with a timeframe of 12 months from the board's approval [1] - The H-share listing is subject to further approval from the board, shareholders, and relevant regulatory bodies including the China Securities Regulatory Commission and the Hong Kong Stock Exchange [1] Group 2 - The company was listed on the Shanghai Stock Exchange's Sci-Tech Innovation Board on November 15, 2019, with an issuance of 83.47 million shares at a price of 18.26 yuan per share [2] - The total funds raised from the initial public offering amounted to 152.42 million yuan, with a net amount of 145.02 million yuan after deducting issuance costs [2] - The funds raised were intended for various projects including the production line for inorganic ceramic nanofiltration membranes and a research center for membrane materials and technology [2][3]